您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (4): 91-98.doi: 10.6040/j.issn.1671-7554.0.2021.1451

• 公共卫生与管理学 • 上一篇    

左西孟旦和米力农治疗重症心力衰竭合并肾损伤患者711例的药物经济学评价

董雪1,2,3,赵霞4,程子捷5,韩毅4   

  • 发布日期:2022-04-22
  • 通讯作者: 韩毅. E-mail:15552565120 @163.com
  • 基金资助:
    山东省重点研发计划(2020RKB14165);山东省千佛山医院培育基金(QYPY2020NSFC0813)

Pharmacoeconomic evaluation of levosimendan and milrinone in the treatment of 711 patients with severe heart failure complicated with renal injury

DONG Xue1,2,3, ZHAO Xia4, CHENG Zijie5, HAN Yi4   

  1. 1. Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan 250012, Shandong, China;
    3. Department of Education, The First Affiliated Hospital of Shandong First Medical University &
    Shandong Provincial Qianfoshan Hospital, Jinan 250014, Shandong, China;
    4. Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University &
    Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan 250014, Shandong, China;
    5. Department of Clinical Pharmacy, School of Basic Medicine, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
  • Published:2022-04-22

PDF (PC)

56

摘要： 目的 比较左西孟旦和米力农用于重症心力衰竭合并正常、轻度损伤肾功能和中度损伤肾功能患者的药物经济学差异。 方法 回顾性收集2016年12月至2019年9月在山东省千佛山医院心血管内科住院并应用左西孟旦或米力农的711例患者信息,先按照肾功能分为肾功能中度损伤组(n=299)和肾功能正常或轻度损伤组(n=412),再根据所使用的正性肌力药物分为左西孟旦亚组和米力农亚组。通过电子病历系统和随访等方式收集患者给药后30 d的临床效果。构建决策树分析模型,分别以30 d内无不良临床事件发生率的显效率、30 d内无死亡事件发生的有效率作为效果指标,以贴现调整后的住院总费用作为成本,进行成本-效果分析和敏感性分析。 结果 肾功能中度损伤组:以显效率为指标,米力农具有绝对的药物经济学优势;以有效率为指标,左西孟旦每比米力农多增加1%的有效率,住院总费用需要多花4 562.64元。肾功能正常或轻度损伤组:左西孟旦住院总费用低于米力农,米力农每比左西孟旦增加1%的显效率,住院总费用需要多花400.89元;每比左西孟旦增加1%的有效率,住院总费用需要多花1 751.16元。敏感性分析结果稳健。 结论 基于真实世界数据研究发现,对于中度肾功能损伤患者,米力农较左西孟旦具有经济学优势;对于正常或轻度损伤肾功能患者,左西孟旦较米力农有一定经济学优势。

关键词: 重症心力衰竭, 左西孟旦, 米力农, 成本-效果分析, 决策树模型, 药物经济学

Abstract: Objective To investigate the cost-effectiveness differences between levosimendan and milrinone in treating severe heart failure complicated with normal, mild and moderate impaired renal function. Methods A total of 711 patients hospitalized in the Cardiology Department of Shandong Provincial Qianfoshan Hospital due to severe heart failure during Dec. 2016 and Sep. 2019 were enrolled. According to the renal function, the patients were divided into moderate renal injury group(n=299)and normal renal function or mild renal injury group(n=412), and then divided into levosimendan subgroup and milrinone subgroup. The information and clinical outcomes of patients 30 days after drug use were collected through the electronic medical record system and follow-up visits. With “obvious efficiency” with no adverse clinical events, and “efficiency” with no death within 30 days as effectiveness indexes, and the discount adjusted total hospitalization cost as the cost index, a decision tree analysis model was constructed, and cost-effectiveness analysis and one-way sensitivity analysis were performed. Results In the moderate renal injury group, with “obvious efficiency” as the effectiveness index, milrinone had absolute pharmacoeconomic advantages; with “efficiency” as the effectiveness index, each 1% more efficiency of levosimendan costed ￥4 562.64 more than that of milrinone. In the normal renal function or mild renal injury group, the total hospitalization cost of levosimendan was lower than that of milrinone, and each 1% increase in obvious efficiency of milrinone costed ￥400.89 more than that of levosimendan, and each 1% increase in efficiency of milrinone costed ￥1 751.16 more than that of levosimendan. The sensitivity analysis results were robust. Conclusion Based on real-world data, milrinone has an economic advantage over levosimendan in severe heart failure patients with moderate renal injury. For patients with normal renal function or mild renal injury, levosimendan has a moderate economic advantage over milrinone.

Key words: Severe heart failure, Levosimendan, Milrinone, Cost-effectiveness analysis, Decision tree model, Pharmacoeconomics

中图分类号: 

  • R956
[1] Bistola V, Arfaras-Melainis A, Polyzogopoulou E, et al. Inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice [J]. Card Fail Rev, 2019, 5(3): 133-139.
[2] Chan CC, Lee KT, Ho WJ, et al. Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study [J]. Ann Intensive Care, 2021, 11(1): 27.
[3] 兰洪涛, 贾旭, 童洲杰,等. 无选择性152例成年慢性心力衰竭患者再入院的危险因素[J]. 山东大学学报(医学版), 2021, 59(4): 63-69. LAN Hongtao, JIA Xu, TONG Zhoujie, et al. Readmission prediction of 152 non-selective adult patients with chronic heart failure [J]. Jouranl of Shandong University(Health Sciences), 2021, 59(4): 63-69.
[4] 王华, 李莹莹, 柴坷, 等. 中国住院心力衰竭患者流行病学及治疗现状[J]. 中华心血管病杂志, 2019, 47(11): 865-874. WANG Hua, LI Yingying, CHAI Ke, et al. Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinicalpractice in China [J]. Chinese Journal of Cardiology, 2019, 47(11): 865-874.
[5] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志, 2018, 2(4): 196-225.
[6] Nandkeolyar S, Ryu R, Mohammad A, et al. A review of inotropes and inopressors for effective utilization in patients with acute decompensated heart failure [J]. J Cardiovasc Pharmacol, 2021, 78(3): 336-345.
[7] Tholén M, Ricksten SE, Lannemyr L. Effects of levosimendan on renal blood flow and glomerular filtration in patients with acute kidney injury after cardiac surgery: a double blind, randomized placebo-controlled study [J]. Crit Care, 2021, 25(1): 207.
[8] Cholley B, Levy B, Fellahi JL, et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper [J]. Crit Care, 2019, 23(1): 385.
[9] 沈晓红. 比较左西孟旦与多巴酚丁胺治疗老年急性心力衰竭的效果及药物经济学分析[J]. 中国乡村医药, 2018, 25(24): 38-39.
[10] 曹俊强, 李彩霞, 赵习玲,等. 米力农与左西孟旦治疗难治性心力衰竭的效果对比[J]. 中国实用医刊, 2021, 48(3): 103-105. CAO Junqiang, LI Caixia, ZHAO Xiling, et al. Comparison on effect of milrinone versus levosimendan on refractory heart failure [J]. Chinese Journal of Practical Medicine, 2021, 48(3): 103-105.
[11] 汪佩, 姬新才. 米力农治疗心力衰竭的临床进展[J]. 世界最新医学信息文摘(连续型电子期刊), 2021, 21(10): 127-129. WANG Pei, JI Xincai. Clinical progress of milrinonein the treatment of heart failure [J]. World Latest Medicine Information(Electronic Version), 2021, 21(10): 127-129.
[12] 李志勇. 左西孟旦和米力农治疗慢性心衰急性发作的临床疗效对比分析[J]. 临床医药文献电子杂志, 2019, 6(41): 5, 7. LI Zhiyong. A comparative analysis of the clinical efficacy of levosimendan and milrinone in the treatment of acute episodes of chronic heart failure [J]. Electronic Journal of Clinical Medical Literature, 2019, 6(41): 5, 7.
[13] 修志贞. 左西孟旦与米力农治疗对重症顽固性心衰患者血清脑钠肽及尿酸水平的影响[J]. 世界最新医学信息文摘(连续型电子期刊), 2021, 21(14): 169-170.
[14] 胡学松, 冷利华. 左西孟旦与米力农注射液治疗老年失代偿性心力衰竭临床疗效的对比研究[J]. 实用心脑肺血管病杂志, 2017, 25(8): 78-81. HU Xuesong, LENG Lihua. Comparative study for clinical effect in treating elderly patients with decompensated heart failure between levosimendan and milrinone injection [J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2017, 25(8): 78-81.
[15] Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use [J]. J Cardiovasc Pharmacol, 2020, 76(1): 4-22.
[16] Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for hemodynamic support after cardiac surgery[J]. N Engl J Med, 2017, 376(21): 2021-2031.
[17] Pisano A, Monti G, Landoni G. Levosimendan: new indications and evidence for reduction in perioperative mortality?[J]. Curr Opin Anaesthesiol, 2016, 29(4): 454-461.
[18] 王治, 李益民, 严雪娇, 等. 139例慢性心力衰竭患者肾功能及预后分析[J]. 中国心血管病研究, 2017, 15(8): 706-709. WANG Zhi, LI Yimin,YAN Xuejiao, et al. Analysis of renal function and its effect on clinical prognosis in 139 patients with heart failure [J]. Chinese Journal of Cardiovaseftlar Research, 2017, 15(8): 706-709.
[19] Gist KM, Goldstein SL, Joy MS, et al. Milrinone dosing issues in critically ill children with kidney injury: a review [J]. J Cardiovasc Pharmacol, 2016, 67(2): 175-181.
[20] Zima E, Farmakis D, Pollesello P, et al. Differential effects of inotropes and inodilators on renal function in acute cardiac care [J]. Eur Heart J Suppl, 2020, 22(Suppl D): D12-D19.
[21] 田艳平, 崔向丽, 刘丽宏,等. 基于决策树模型对我国6种保肝药物治疗药物性肝损伤的成本-效果分析[J]. 中国药物应用与监测, 2018, 15(3): 131-135. TIAN Yanping, CUI Xiangli, LIU Lihong, et al. Cost-effectiveness analysis of the six kinds of hepatoprotective drugs in the treatment of drug-induced liver injury in China based on the decision tree model [J]. Chinese Journal of Drug Application and Monitoring, 2018, 15(3): 131-135.
[22] 李洪超. 基于文献的药物经济学评价: 方法和挑战[J]. 药学与临床研究, 2016, 24(2): 188-191.
[23] 张楠, 石学峰, 吴晶. 增量成本效果比在卫生技术评估中的应用[J]. 中国卫生政策研究, 2012, 5(2): 64-68. ZHANG Nan, SHI Xuefeng, WU Jing. The application of incremental cost-effectiveness ratio to health technology assessment[J]. Chinese Journal of Health Policy, 2012, 5(2): 64-68.
[24] 刘霄岩. 米力农治疗难治性心力衰竭80例临床观察[J]. 山东大学学报(医学版), 2014, 52(z2): 61, 63.
[25] Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in Clinical Use [J]. Card Fail Rev, 2020, 6: e19. doi: 10.15420/cfr.2020.03.
[26] Sangalli F, Bellani G, Affronti A, et al. Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions [J]. Minerva Anestesiol, 2020, 86(6): 645-651.
[1] 许天一,吴萍,王爱玲,陈丽萍. 米力农雾化治疗小儿重症肺炎合并心力衰竭的疗效[J]. 山东大学学报（医学版）, 2016, 54(7): 88-90.
[2] 刘霄岩. 米力农治疗难治性心力衰竭80例临床观察[J]. 山东大学学报（医学版）, 2014, 52(S2): 61-61.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 徐歌,李青,张灿灿,田永杰. 子宫腺肌病组织及原代细胞中PARP-1、HIF-1α的表达及临床意义[J]. 山东大学学报 (医学版), 2022, 60(4): 55 -61 .
[2] 陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30 -37 .
[3] 邵娜,殷昊,李亚冉,张保坤,黄伟伟,鲁珊珊,唐吉友. Suvorexant改善慢性睡眠剥夺小鼠学习记忆损害的机制探讨[J]. 山东大学学报 (医学版), 2022, 60(4): 17 -23 .
[4] 赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24 -29 .
[5] 杨丛品,罗卓野,许秀华,李爱民,郝桂敏. 河北省某医院体检3 512例育龄女性生育选择及压力现状[J]. 山东大学学报 (医学版), 2022, 60(4): 62 -67 .
[6] 赵海龙,王皓,方雨晴,毛飞,赵张宁,田祥奇,徐新荣,王敏,李秀华. 增服艾地苯醌对34例帕金森病抑郁患者的疗效观察[J]. 山东大学学报 (医学版), 2022, 60(4): 38 -44 .
[7] 李鸿皓,于晶,陈亚丽,郭守刚. 20例NMOSD患者CD4+CD25+FoxP3+调节性T细胞数量和FoxP3 mRNA的表达水平[J]. 山东大学学报 (医学版), 2022, 60(4): 50 -54 .
[8] 刘丽雯,马俊,李沛铮,张秀芳,刘艺鸣. 128例帕金森病照料者负担及影响因素[J]. 山东大学学报 (医学版), 2022, 60(4): 45 -49 .
[9] 孙继业,王紫欧,孙晓伟,李洪涛. 中药熏蒸联合体外冲击波对72例髋关节撞击综合征临床疗效、血清炎症因子水平的影响[J]. 山东大学学报 (医学版), 2022, 60(4): 76 -81 .
[10] 袁宏涛,纪淙山,康冰,秦松楠,于鑫鑫,高琳,王锡明. CT影像组学对肾上腺乏脂腺瘤与结节样增生的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(4): 68 -75 .
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发